1.中山大学医学院医学遗传室, 广东 深圳 518107
2.中山大学中山医学院医学遗传室, 广东 广州 510080
3.广东省生殖科学研究所, 广东 广州 510600
郑诗瑶,硕士生,研究方向:遗传性骨病的诊防,E-mail:zhengshy36@mail2.sysu.edu.cn
纸质出版日期:2023-05-20,
收稿日期:2023-03-17,
扫 描 看 全 文
郑诗瑶,唐佳,艾阳等.中国南方三个Hunter综合征家系的病因学研究[J].中山大学学报(医学科学版),2023,44(03):490-496.
ZHENG Shi-yao,TANG Jia,AI Yang,et al.The Etiological Study of Three Hunter Syndrome Families in Southern China[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(03):490-496.
郑诗瑶,唐佳,艾阳等.中国南方三个Hunter综合征家系的病因学研究[J].中山大学学报(医学科学版),2023,44(03):490-496. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0317.
ZHENG Shi-yao,TANG Jia,AI Yang,et al.The Etiological Study of Three Hunter Syndrome Families in Southern China[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(03):490-496. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0317.
目的
2
揭示中国南方3个Hunter综合征家系的分子发病机制,阐明患者表型和基因型的相关性,为今后的产前或植入前基因诊断奠定基础。
方法
2
在临床初诊和系谱分析的基础上,首先进行尿糖胺聚糖定性检测,然后抽取患儿及其亲属的抗凝血,提取DNA并通过PCR、Sanger测序对
IDS
基因进行序列分析。对发现的新变异采用RT-PCR和生物信息分析等多种方法进行致病性鉴定。
结果
2
3个家系的患者尿检结果均为强阳性(++)。家系1~3先证者为男性,
IDS
基因均发生半合子突变且突变均来自其母,突变位点分别为:c.615_622delCATACAGT,c.847_848delGT和IVS7 ds+1 G
>
A。跨物种保守性分析结果显示
IDS
基因突变部位所在的氨基酸在物种进化过程中具有高度保守性。与正常蛋白相比,突变蛋白的高级结构预测结果存在明显差异。根据ACMG标准,3个家系的变异均为致病性突变。
结论
2
先证者所患疾病为Hunter综合征,
IDS
基因的c.615_622del(p.Ile206Valfs
*
18)、c.847_848del(p.Val283Alafs
*
57)和IVS7 ds+1 G
>
A (p.G336Dfs*12)均是新的致病性突变,它们是引起患儿发病的内在原因。本研究进一步丰富了
IDS
基因的突变谱。
Objective
2
To reveal the molecular pathogenesis of Hunter syndrome in three families in southern China and to clarify the correlation between phenotype and genotype, so as to lay a foundation for future prenatal or preimplantation genetic diagnosis.
Methods
2
On the basis of initial clinical diagnosis and pedigree analysis, qualitative detection of glycosaminoglycans in urine was performed first, and then anticoagulant blood samples were collected from the children and their relatives. DNA was extracted and the
IDS
gene sequence was analyzed by PCR and Sanger sequencing. Various methods such as RT-PCR and bioinformatics analysis were used to identify the pathogenicity of the new variants.
Results
2
The urine test results of the patients in the three families were all strongly positive(++). Probands were all male, with hemizygous mutations in
IDS
gene from their mothers, and the mutation sites were c.615_622delCATACAGT, c.847_848delGT and IVS7 ds+1 G
>
A, respectively. The cross-species conservation analysis showed that the amino acid of
IDS
gene mutation site was highly conserved during species evolution. Compared with the normal protein, mutant proteins exhibited significant differences in the predicted results of advanced structure. The variants identified in the three families were classified as pathogenic by ACMG criteria.
Conclusions
2
The three probands were diagnosed with Hunter syndrome. The c.615_622del(p.Il206Valfs*18), c.847_848del(p.Val283Alafs*57) and IVS7 ds+1 G
>
A (p.G336Dfs*12) of
IDS
gene are all novel pathogenic mutations, which are the underlying causes of morbidity in children. This study has further enriched the mutation spectrum of
IDS
gene.
Hunter综合征IDS基因艾杜糖-2-硫酸酯酶新突变
Hunter syndromeIDS geneiduronate-2-sulfatasenovel mutation
Guo YB, Pan JX, Meng YX. A new mutation (1062 del 16) of iduronate-2-sulfatase gene from a Chinese patient with hunter syndrome[J]. J Zhejiang Univ Sci B, 2007, 8(8): 566-569.
Matsuhisa K, Imaizumi K. Loss of function of mutant IDS due to endoplasmic reticulum-associated degradation: new therapeutic opportunities for mucopolysaccharidosis type II[J]. Int J Mol Sci, 2021, 22(22): 12227.
黄艳, 孟亚仙, 郭奕斌. 微量快速检测尿GAG方法的建立[J]. 中山大学学报论丛, 2007(3): 138-140.
Huang Y, Meng YX, Guo YB. Establishment of a method for rapid detection of GAG in microurine[J]. J Sun Yat-sen Univ Forum, 2007(3): 138-140.
Madeira F, Pearce M, Tivey ARN, et al. Search and sequence analysis tools services from EMBL-EBI in 2022[J]. Nucleic Acids Res, 2022, 50(W1): W276-W279.
Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes[J]. Nucleic Acids Res, 2018, 46(W1): W296-W303.
Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera—a visualization system for exploratory research and analysis[J]. J Comput Chem, 2004, 25(13): 1605-1612.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology[J]. Genet Med, 2015, 17(5): 405-424.
王秋菊, 沈亦平, 邬玲仟, 等. 遗传变异分类标准与指南[J]. 中国科学: 生命科学, 2017, 47(6): 668-688.
Wang QJ, Shen YP, Wu LQ, et al. Standards and guidelines for the interpretation of sequence variants[J]. Sci Sin(Vitae), 2017, 47(6): 668-688.
Hunter C. A rare disease in two brothers[J]. Proc R Soc Med, 1917, 10(Sect Study Dis Child): 104-116.
Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision[J]. Am J Med Genet A, 2019, 179(12): 2393-2419.
中华医学会儿科学分会内分泌遗传代谢学组. 黏多糖贮积症Ⅱ型临床诊断与治疗专家共识[J]. 中华儿科杂志, 2021, 59(6): 446-451.
The Subspecialty Group of Endocrinologic, Hereditary and Metabolic Diseases, The Society of Pediatrics, Chinese Medical Association. Experts consensus on diagnosis and treatment of mucopolysaccharidosis type Ⅱ[J]. Chin J Pediatr, 2021, 59(6): 446-451.
D'Avanzo F, Rigon L, Zanetti A, et al. Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment[J]. Int J Mol Sci, 2020, 21(4): 1258.
Mohamed S, He QQ, Singh AA, et al. Mucopolysaccharidosis type II (hunter syndrome): clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment[J]. Adv Carbohydr Chem Biochem, 2020, 77: 71-117.
Scarpa M, Almássy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease[J]. Orphanet J Rare Dis, 2011, 6: 72.
Sousa Martins R, Rocha S, Guimas A, et al. Hunter syndrome: the phenotype of a rare storage disease[J]. Cureus, 2022, 14(2): e21985.
Wraith JE, Cooper A, Thornley M, et al. The clinical phenotype of two patients with a complete deletion of the iduronate-2-sulphatase gene (mucopolysaccharidosis II—hunter syndrome) [J]. Hum Genet, 1991, 87(2): 205-206.
Zhang Z, Ma M, Zhang W, et al. Phenotypic and genetic characteristics of 130 patients with mucopolysaccharidosis type II: a single-center retrospective study in China[J]. Front Genet, 2023, 14: 1103620.
Demydchuk M, Hill CH, Zhou A, et al. Insights into hunter syndrome from the structure of iduronate-2-sulfatase[J]. Nat Commun, 2017, 8: 15786.
Lin HY, Tu RY, Chern SR, et al. Identification and functional characterization of IDS gene mutations underlying Taiwanese hunter syndrome (mucopolysaccharidosis type II) [J]. Int J Mol Sci, 2019, 21(1): 114.
Verma S, Pantoom S, Petters J, et al. A molecular genetics view on mucopolysaccharidosis type II[J]. Mutat Res, 2021, 788: 108392.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构